1. Home
  2. GNPX vs MGN Comparison

GNPX vs MGN Comparison

Compare GNPX & MGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$3.95

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

MGN

Megan Holdings Limited Ordinary Shares

HOLD

Current Price

$0.10

Market Cap

2.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
MGN
Founded
2009
2020
Country
United States
Malaysia
Employees
13
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
2.6M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
GNPX
MGN
Price
$3.95
$0.10
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
131.5K
38.0M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$32.33
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.06
52 Week High
$12.97
$5.18

Technical Indicators

Market Signals
Indicator
GNPX
MGN
Relative Strength Index (RSI) 45.44 49.19
Support Level $0.73 $0.06
Resistance Level $5.24 $0.16
Average True Range (ATR) 0.56 0.03
MACD -0.26 0.00
Stochastic Oscillator 10.66 26.57

Price Performance

Historical Comparison
GNPX
MGN

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About MGN Megan Holdings Limited Ordinary Shares

Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.

Share on Social Networks: